TY - JOUR
T1 - Intraocular pressure spikes following neodymium-doped yttrium aluminum garnet laser capsulotomy
T2 - Current prevalence and management in Israel
AU - Achiron, Asaf
N1 - Publisher Copyright:
© 2017, Jaypee Brothers Medical Publishers (P) Ltd. All rights reserved.
PY - 2017/5/1
Y1 - 2017/5/1
N2 - Aim: The current treatment for posterior capsular opacification (PCO), neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy, may lead to increased intraocular pressure (IOP). Our aim was to survey routines in the management of IOP spikes and to identify the rate of IOP spikes following prophylactic apraclonidine treatment. Materials and methods A survey questionnaire among ophthalmologists and a retrospective registry review was used. Patients were administered apraclonidine 0.5% prior to capsulotomy. The IOP was measured before and 1 hour postprocedure. Results: A total of 71% of responders (n = 45) routinely prescribe topical IOP-lowering medication and 82% routinely measure IOP before or after capsulotomy. The registry analysis included 87 eyes of 75 patients. Mean IOP decreased by 0.9 ± 3.3 mm Hg (p = 0.01, range: -6 to 10) following capsulotomy. No patient reached IOP values above 21 mm Hg following the procedure, with 3.4 and 1.1% of patients demonstrating an IOP elevation of more than 3 and 5 mm Hg respectively. No association was found between number of laser shots, mean laser power, or comorbid conditions, such as diabetes, hypertension, or Glaucoma status with posttreatment IOP. Conclusion: Most ophthalmologists surveyed routinely prescribe prophylactic IOP-lowering medication and measure IOP before or after capsulotomy. Mean IOP remained clinically stable following capsulotomy with prophylactic apraclonidine instillation, and no patient reached IOP values above 21 mm Hg. Differences in laser delivery or comorbid conditions were not associated with posttreatment IOP. Considering that no patient demonstrated a clinically significant IOP spike following prophylactic apraclonidine instillation, perhaps routine measurement of IOP following primary Nd: YAG laser may be reserved for high-risk patients only. Clinical significance: In this work, we showed the prophylactic effect of apraclonidine 0.5% and suggest that measuring IOP after the procedure is necessary only in certain high-risk cases, possibly helping to reduce workload and patient waiting time and improving quality of service.
AB - Aim: The current treatment for posterior capsular opacification (PCO), neodymium-doped yttrium aluminum garnet (Nd: YAG) laser capsulotomy, may lead to increased intraocular pressure (IOP). Our aim was to survey routines in the management of IOP spikes and to identify the rate of IOP spikes following prophylactic apraclonidine treatment. Materials and methods A survey questionnaire among ophthalmologists and a retrospective registry review was used. Patients were administered apraclonidine 0.5% prior to capsulotomy. The IOP was measured before and 1 hour postprocedure. Results: A total of 71% of responders (n = 45) routinely prescribe topical IOP-lowering medication and 82% routinely measure IOP before or after capsulotomy. The registry analysis included 87 eyes of 75 patients. Mean IOP decreased by 0.9 ± 3.3 mm Hg (p = 0.01, range: -6 to 10) following capsulotomy. No patient reached IOP values above 21 mm Hg following the procedure, with 3.4 and 1.1% of patients demonstrating an IOP elevation of more than 3 and 5 mm Hg respectively. No association was found between number of laser shots, mean laser power, or comorbid conditions, such as diabetes, hypertension, or Glaucoma status with posttreatment IOP. Conclusion: Most ophthalmologists surveyed routinely prescribe prophylactic IOP-lowering medication and measure IOP before or after capsulotomy. Mean IOP remained clinically stable following capsulotomy with prophylactic apraclonidine instillation, and no patient reached IOP values above 21 mm Hg. Differences in laser delivery or comorbid conditions were not associated with posttreatment IOP. Considering that no patient demonstrated a clinically significant IOP spike following prophylactic apraclonidine instillation, perhaps routine measurement of IOP following primary Nd: YAG laser may be reserved for high-risk patients only. Clinical significance: In this work, we showed the prophylactic effect of apraclonidine 0.5% and suggest that measuring IOP after the procedure is necessary only in certain high-risk cases, possibly helping to reduce workload and patient waiting time and improving quality of service.
KW - Apraclonidine
KW - Cataract surgery
KW - Intraocular pressure
KW - Neodymium-doped yttrium aluminum garnet laser capsulotomy
KW - Posterior capsular opacification
UR - http://www.scopus.com/inward/record.url?scp=85046070625&partnerID=8YFLogxK
U2 - 10.5005/jp-journals-10028-1225
DO - 10.5005/jp-journals-10028-1225
M3 - ???researchoutput.researchoutputtypes.contributiontojournal.article???
AN - SCOPUS:85046070625
SN - 0974-0333
VL - 11
SP - 63
EP - 66
JO - Journal of Current Glaucoma Practice
JF - Journal of Current Glaucoma Practice
IS - 2
ER -